Algert Global LLC Trims Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Algert Global LLC trimmed its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 1.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 448,206 shares of the company’s stock after selling 4,518 shares during the period. Algert Global LLC owned about 0.14% of Amneal Pharmaceuticals worth $3,729,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its holdings in shares of Amneal Pharmaceuticals by 16.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,404,883 shares of the company’s stock valued at $11,689,000 after purchasing an additional 202,863 shares during the period. Intech Investment Management LLC purchased a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter worth $307,000. Segall Bryant & Hamill LLC grew its position in shares of Amneal Pharmaceuticals by 1.6% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 489,162 shares of the company’s stock worth $4,070,000 after buying an additional 7,661 shares in the last quarter. Quest Partners LLC purchased a new position in shares of Amneal Pharmaceuticals during the third quarter valued at $84,000. Finally, Gladius Capital Management LP bought a new stake in shares of Amneal Pharmaceuticals in the third quarter valued at about $37,000. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Trading Down 0.1 %

NASDAQ AMRX opened at $8.38 on Tuesday. The firm’s fifty day simple moving average is $8.56 and its two-hundred day simple moving average is $7.75. The firm has a market capitalization of $2.60 billion, a P/E ratio of -12.32 and a beta of 1.17. Amneal Pharmaceuticals, Inc. has a 12-month low of $4.16 and a 12-month high of $9.48.

Insider Transactions at Amneal Pharmaceuticals

In related news, SVP Jason B. Daly sold 43,657 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $8.61, for a total value of $375,886.77. Following the completion of the transaction, the senior vice president now directly owns 13,665 shares of the company’s stock, valued at $117,655.65. This trade represents a 76.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 17.46% of the company’s stock.

Wall Street Analyst Weigh In

AMRX has been the topic of a number of research reports. StockNews.com raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 11th. Piper Sandler boosted their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Truist Financial increased their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, October 2nd. Barclays boosted their price target on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective for the company in a research note on Friday, September 6th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $10.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.